Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IC51 Booster Dose for Japanese Encephalitis
NCT00595309Phase 3Completed
- Sponsor
- Valneva
- Start
- Dec 2007
- Primary completion
- Oct 2009
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of Japanese encephalitis inactivated vaccine in Japanese encephalitis (JE), sponsored by Valneva. Primary endpoint: Seroconversion Rate at Month 12. Started Dec 2007; status: completed.
02
Drugs
Japanese encephalitis inactivated vaccine
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT00595309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00595309.